FASN and neoplasm: The maximum reduction in tumor weight in response to TVB-3664 treatment achieved in our study was 50% which is significantly less than the >80% reduction in tumor growth in non-small-cell lung cancer PDXs treated with TVB-3166 [12] suggesting that lung cancer may be more susceptible to FASN inhibition.